ORCID Profile
0000-0002-3666-5261
Current Organisations
Deakin University
,
Eastern Health
,
University of Melbourne
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: BMJ
Date: 05-2022
DOI: 10.1136/BMJOPEN-2022-060869
Abstract: Gender affirming hormone therapy (GAHT) is increasingly used by transgender in iduals and leads to shifts in sex hormone levels. Skeletal muscle is highly responsive to hormone activity, with limited data on the effects of GAHT on different human tissues. Here, we present the protocol for the GAME study (the effects of G ender A ffirming hormone therapy on skeletal M uscle training and E pigenetics), which aims to uncover the effects of GAHT on skeletal muscle ‘omic’ profiles (methylomics, transcriptomics, proteomics, metabolomics) and markers of skeletal muscle health and fitness. This study is a prospective age-matched cohort study in transgender adults commencing GAHT (n=80) and age-matched in iduals not commencing GAHT (n=80), conducted at Austin Health and Victoria University in Victoria, Australia. Assessments will take place prior to beginning GAHT and 6 and 12 months into therapies in adults commencing GAHT. Age-matched in iduals will be assessed at the same time points. Assessments will be ided over three examination days, involving (1) aerobic fitness tests, (2) muscle strength assessments and (3) collection of blood and muscle s les, as well as body composition measurements. Standardised diets, fitness watches and questionnaires will be used to control for key confounders in analyses. Primary outcomes are changes in aerobic fitness and muscle strength, as well as changes in skeletal muscle DNA methylation and gene expression profiles. Secondary outcomes include changes in skeletal muscle characteristics, proteomics, body composition and blood markers. Linear mixed models will be used to assess changes in outcomes, while accounting for repeated measures within participants and adjusting for known confounders. The Austin Health Human Research Ethics Committee (HREC) and Victoria University HREC granted approval for this study (HREC/77146/Austin-2021). Findings from this project will be published in open-access, peer-reviewed journals and presented to scientific and public audiences. ACTRN12621001415897 Pre-results.
Publisher: MDPI AG
Date: 13-12-2019
Abstract: There is an increasing demand for trans and gender erse (TGD) health services worldwide. Given the unique and erse healthcare needs of the TGD community, best practice TGD health services should be community-led. We aimed to understand the healthcare needs of a broad group of TGD Australians, how health professionals could better support TGD people, and gain an understanding of TGD-related research priorities. An anonymous online survey received 928 eligible responses from TGD Australian adults. This paper focuses on three questions out of that survey that allowed for free-text responses. The data were qualitatively coded, and overarching themes were identified for each question. Better training for healthcare professionals and more accessible transgender healthcare were the most commonly reported healthcare needs of participants. Findings highlight a pressing need for better training for healthcare professionals in transgender healthcare. In order to meet the demand for TGD health services, more gender services are needed, and in time, mainstreaming health services in primary care will likely improve accessibility. Evaluation of training strategies and further research into optimal models of TGD care are needed however, until further data is available, views of the TGD community should guide research priorities and the TGD health service delivery.
Publisher: BMJ
Date: 12-2022
DOI: 10.1136/BMJOPEN-2022-065568
Abstract: To determine the negative predictive value (NPV) of the FebriDx point-of-care host response device in patients presenting with symptoms suggestive of COVID-19 infection in a mostly immunised Australian emergency department (ED) population during the late 2021 phase of the COVID-19 pandemic. Observational diagnostic accuracy study comparing FebriDx point-of-care test to SARS-CoV-2 PCR. An ED in Melbourne, Australia, with 63 000 annual presentations in 2021. Patients aged 16 and over who met the Victorian Department of Health case definition for suspected COVID-19 infection PCR testing. Patients meeting any of the following criteria were excluded: years of age acute respiratory symptom(s) with onset days prior to testing current immunosuppressive or interferon therapy live immunisation within the last 30 days fever lasting days antibiotic or antiviral use in the preceding 14 days experience of major trauma, major surgical intervention or severe burns within the last 30 days. COVID-19 PCR results (detected, not detected) and FebriDx results (bacterial positive, viral negative, viral positive). 94 participants were enrolled (female: 46 male: 48), 34% of participants (tested positive for COVID-19 according to PCR results, with a background incidence among all adult ED attenders of 2.5%. The sensitivity of FebriDx for detection of COVID-19 was 56% (95% CI 40% to 100%) and specificity was 92% (95% CI 84% to 100%). For the population tested, this resulted in an NPV of 80% (95% CI 71% to 100%) and a positive predictive value of 78% (95% CI 60% to 100%). In the context of a population with low COVID-19 infection rates, an evolved variant of COVID-19 and a very high community COVID-19 vaccination rate, FebriDx demonstrated reduced sensitivity and NPV relative to results from earlier international tests. These contextual factors should be considered during any attempt to generalise the current results. ACTRN12620001029987 (Australian Clinical Trials).
Publisher: Informa UK Limited
Date: 11-03-2023
Publisher: The Endocrine Society
Date: 13-07-2023
Abstract: The inclusion of transgender people in elite sport has been a topic of debate. This narrative review examines the impact of gender-affirming hormone therapy (GAHT) on physical performance, muscle strength, and markers of endurance. MEDLINE and Embase were searched using terms to define the population (transgender), intervention (GAHT), and physical performance outcomes. Existing literature comprises cross-sectional or small uncontrolled longitudinal studies of short duration. In nonathletic trans men starting testosterone therapy, within 1 year, muscle mass and strength increased and, by 3 years, physical performance (push-ups, sit-ups, run time) improved to the level of cisgender men. In nonathletic trans women, feminizing hormone therapy increased fat mass by approximately 30% and decreased muscle mass by approximately 5% after 12 months, and steadily declined beyond 3 years. While absolute lean mass remains higher in trans women, relative percentage lean mass and fat mass (and muscle strength corrected for lean mass), hemoglobin, and VO2 peak corrected for weight was no different to cisgender women. After 2 years of GAHT, no advantage was observed for physical performance measured by running time or in trans women. By 4 years, there was no advantage in sit-ups. While push-up performance declined in trans women, a statistical advantage remained relative to cisgender women. Limited evidence suggests that physical performance of nonathletic trans people who have undergone GAHT for at least 2 years approaches that of cisgender controls. Further controlled longitudinal research is needed in trans athletes and nonathletes.
Publisher: Mary Ann Liebert Inc
Date: 2020
Publisher: Mary Ann Liebert Inc
Date: 04-2023
Publisher: Springer Science and Business Media LLC
Date: 08-02-2021
DOI: 10.1186/S12888-021-03084-7
Abstract: Transgender, including gender erse and non-binary people, henceforth referred to collectively as trans people, are a highly marginalised population with alarming rates of suicidal ideation, attempted suicide and self-harm. We aimed to understand the risk and protective factors of a lifetime history of attempted suicide in a community s le of Australian trans adults to guide better mental health support and suicide prevention strategies. Using a non-probability snowball s ling approach, a total of 928 trans adults completed a cross-sectional online survey between September 2017 and January 2018. The survey assessed demographic data, mental health morbidity, a lifetime history of intentional self-harm and attempted suicide, experiences of discrimination, experiences of assault, access to gender affirming healthcare and access to trans peer support groups. Logistic regression was used to examine the risk or protective effect of participant characteristics on the odds of suicide. Of 928 participants, 73% self-reported a lifetime diagnosis of depression, 63% reported previous self-harm, and 43% had attempted suicide. Higher odds of reporting a lifetime history of suicide attempts were found in people who were unemployed (adjusted odds ratio (aOR) 1.54 (1.04, 2.28), p = 0.03), had a diagnosis of depression (aOR 3.43 (2.16, 5.46), p 0.001), desired gender affirming surgery in the future (aOR 1.71 (1.134, 2.59), p = 0.01), had experienced physical assault (aOR 2.00 (1.37, 2.93), p 0.001) or experienced institutional discrimination related to their trans status (aOR 1.59 (1.14, 2.22), p = 0.007). Suicidality is associated with desiring gender affirming surgery in the future, gender based victimisation and institutionalised cissexism. Interventions to increase social inclusion, reduce transphobia and enable access to gender affirming care, particularly surgical interventions, are potential areas of intervention.
No related grants have been discovered for Fang Qi Wong.